FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2971504695> ?p ?o ?g. }

• W2971504695 endingPage "129" @default.
• W2971504695 startingPage "123" @default.
• W2971504695 abstract "Recent evidence from EMBRACE shows that around 16% patients with locally advanced cervical cancer (LACC) have residual tumor in distal parametrium (DP) and pelvic wall disease (LPW) after concurrent radio-chemotherapy (CCRT). Adequate target coverage with standard brachytherapy approaches represents a challenge. Therefore, we modified the Vienna I applicator with an add-on cap allowing for additional oblique needles into the DP/LPW (Vienna II). We report here the feasibility and clinical outcomes using Vienna II applicator in LACC patients treated in 2 institutions.69 patients with residual disease in DP/LPW after CCRT were accrued. FIGO (2009) stage was 26% IIB, 52% III, 15% IVA, 7% IVB (para-aortic nodes). At diagnosis 91% had disease involving DP/LPW. After CCRT, patients underwent image guided adaptive brachytherapy (IGABT) using Vienna II applicator. IGABT details, acute complications, dose volume parameters and clinical outcome variables were compiled and analyzed.Residual DP/LPW disease at BT was found in 90% patients. Median total number of needles were 7 [3-15], oblique 4 [1-7]. Manageable intraoperative utero-vaginal complications occurred in 8 patients and manageable arterial bleeding in 6 patients during removal. Mean distance between tandem and outer contour of CTVHR was 38 mm and mean CTVHR (±SD) volume was 69 ± 32 cm3. The mean D90 CTVHR was 86 ± 7 Gy (EQD2) and mean (±SD) D2cm3 (Gy, EQD2) 86 ± 12, 68 ± 7, 68 ± 9 for bladder, rectum and sigmoid respectively. Actuarial LC, PFS, OS at 3/5 years was 76/72%, 56/50%, 62/54% and G3-4 late toxicities (n = 23) were observed in 14 patients (20%).IGABT using Vienna II applicator allows for appropriate target coverage in tumors extending into DP/LPW at the time of BT. Clinical use is feasible and results in good local control, DFS and OS with moderate rate of acute and late ≥G3 toxicity." @default.
• W2971504695 created "2019-09-12" @default.
• W2971504695 creator A5012456198 @default.
• W2971504695 creator A5018259020 @default.
• W2971504695 creator A5018386754 @default.
• W2971504695 creator A5022443896 @default.
• W2971504695 creator A5041464612 @default.
• W2971504695 creator A5046289076 @default.
• W2971504695 creator A5058848857 @default.
• W2971504695 creator A5067216360 @default.
• W2971504695 creator A5071089813 @default.
• W2971504695 creator A5072760427 @default.
• W2971504695 creator A5077820862 @default.
• W2971504695 creator A5085569334 @default.
• W2971504695 creator A5088916661 @default.
• W2971504695 creator A5091063964 @default.
• W2971504695 creator A5091639043 @default.
• W2971504695 date "2019-12-01" @default.
• W2971504695 modified "2023-10-01" @default.
• W2971504695 title "Vienna-II ring applicator for distal parametrial/pelvic wall disease in cervical cancer brachytherapy: An experience from two institutions: Clinical feasibility and outcome" @default.
• W2971504695 cites W1968972246 @default.
• W2971504695 cites W1982528333 @default.
• W2971504695 cites W1988308847 @default.
• W2971504695 cites W1997612130 @default.
• W2971504695 cites W2033905828 @default.
• W2971504695 cites W2042262831 @default.
• W2971504695 cites W2075401704 @default.
• W2971504695 cites W2079308339 @default.
• W2971504695 cites W2105240431 @default.
• W2971504695 cites W2122321342 @default.
• W2971504695 cites W2128768289 @default.
• W2971504695 cites W2131860931 @default.
• W2971504695 cites W2150558450 @default.
• W2971504695 cites W2155153063 @default.
• W2971504695 cites W2288035998 @default.
• W2971504695 cites W2341208453 @default.
• W2971504695 cites W2345268804 @default.
• W2971504695 cites W2398265141 @default.
• W2971504695 cites W2460848290 @default.
• W2971504695 cites W2484064422 @default.
• W2971504695 cites W2545944736 @default.
• W2971504695 cites W2554147819 @default.
• W2971504695 cites W2675799240 @default.
• W2971504695 cites W2783123637 @default.
• W2971504695 cites W2806978804 @default.
• W2971504695 cites W2809568906 @default.
• W2971504695 cites W4255591201 @default.
• W2971504695 cites W2806268934 @default.
• W2971504695 doi "https://doi.org/10.1016/j.radonc.2019.08.004" @default.
• W2971504695 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/31495516" @default.
• W2971504695 hasPublicationYear "2019" @default.
• W2971504695 type Work @default.
• W2971504695 sameAs 2971504695 @default.
• W2971504695 citedByCount "33" @default.
• W2971504695 countsByYear W29715046952020 @default.
• W2971504695 countsByYear W29715046952021 @default.
• W2971504695 countsByYear W29715046952022 @default.
• W2971504695 countsByYear W29715046952023 @default.
• W2971504695 crossrefType "journal-article" @default.
• W2971504695 hasAuthorship W2971504695A5012456198 @default.
• W2971504695 hasAuthorship W2971504695A5018259020 @default.
• W2971504695 hasAuthorship W2971504695A5018386754 @default.
• W2971504695 hasAuthorship W2971504695A5022443896 @default.
• W2971504695 hasAuthorship W2971504695A5041464612 @default.
• W2971504695 hasAuthorship W2971504695A5046289076 @default.
• W2971504695 hasAuthorship W2971504695A5058848857 @default.
• W2971504695 hasAuthorship W2971504695A5067216360 @default.
• W2971504695 hasAuthorship W2971504695A5071089813 @default.
• W2971504695 hasAuthorship W2971504695A5072760427 @default.
• W2971504695 hasAuthorship W2971504695A5077820862 @default.
• W2971504695 hasAuthorship W2971504695A5085569334 @default.
• W2971504695 hasAuthorship W2971504695A5088916661 @default.
• W2971504695 hasAuthorship W2971504695A5091063964 @default.
• W2971504695 hasAuthorship W2971504695A5091639043 @default.
• W2971504695 hasConcept C121608353 @default.
• W2971504695 hasConcept C126322002 @default.
• W2971504695 hasConcept C126838900 @default.
• W2971504695 hasConcept C141071460 @default.
• W2971504695 hasConcept C146357865 @default.
• W2971504695 hasConcept C151730666 @default.
• W2971504695 hasConcept C2776870353 @default.
• W2971504695 hasConcept C2777416452 @default.
• W2971504695 hasConcept C2778220009 @default.
• W2971504695 hasConcept C2779808985 @default.
• W2971504695 hasConcept C2781074409 @default.
• W2971504695 hasConcept C2910158674 @default.
• W2971504695 hasConcept C2989005 @default.
• W2971504695 hasConcept C2993195994 @default.
• W2971504695 hasConcept C509974204 @default.
• W2971504695 hasConcept C71924100 @default.
• W2971504695 hasConcept C86803240 @default.
• W2971504695 hasConceptScore W2971504695C121608353 @default.
• W2971504695 hasConceptScore W2971504695C126322002 @default.
• W2971504695 hasConceptScore W2971504695C126838900 @default.
• W2971504695 hasConceptScore W2971504695C141071460 @default.
• W2971504695 hasConceptScore W2971504695C146357865 @default.
• W2971504695 hasConceptScore W2971504695C151730666 @default.
• W2971504695 hasConceptScore W2971504695C2776870353 @default.

• next